Risk of subsequent malignant neoplasms in long-term Hereditary retinoblastoma survivors after chemotherapy and radiotherapy Academic Article uri icon

Overview

MeSH Major

  • Neoplasms, Second Primary
  • Retinal Neoplasms
  • Retinoblastoma

abstract

  • This comprehensive quantification of SMN risk after chemotherapy and RT among hereditary Rb survivors also demonstrates an AA-related contribution to risk. Although triethylenemelamine is no longer prescribed, our findings warrant further follow-up to investigate potential SMN risks associated with current chemotherapies used for Rb.

publication date

  • October 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4178525

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.54.7844

PubMed ID

  • 25185089

Additional Document Info

start page

  • 3284

end page

  • 90

volume

  • 32

number

  • 29